PubMed Health⌕ Search

Biomedical subjects

L C Schneider

Publications and source records attributed to L C Schneider.

At least 19 recordsLinked to original sources

A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO).

Hypohidrotic ectodermal dysplasia (HED), a congenital disorder of teeth, hair, and eccrine sweat glands, is usually inherited as an X-linked recessive trait, although rarer autosomal dominant and recessive forms exist. We have studied males from four families with HED and immunodeficiency (HED-ID), in which the disorder segregates as an X-linked recessive trait. Affected males manifest dysgammaglobulinemia and, despite therapy, have significant morbidity and mortality from recurrent infections. Recently, mutations in IKK-gamma (NEMO) have been shown to cause familial incontinentia pigmenti (IP). Unlike HED-ID, IP affects females and, with few exceptions, causes male prenatal lethality. IKK-gamma is required for the activation of the transcription factor known as "nuclear factor kappa B" and plays an important role in T and B cell function. We hypothesize that "milder" mutations at this locus may cause HED-ID. In all four families, sequence analysis reveals exon 10 mutations affecting the carboxy-terminal end of the IKK-gamma protein, a domain believed to connect the IKK signalsome complex to upstream activators. The findings define a new X-linked recessive immunodeficiency syndrome, distinct from other types of HED and immunodeficiency syndromes. The data provide further evidence that the development of ectodermal appendages is mediated through a tumor necrosis factor/tumor necrosis factor receptor-like signaling pathway, with the IKK signalsome complex playing a significant role.

Adolescent↗

Atopic diseases and upper respiratory infections.

This article reviews information on the topics of asthma, atopic dermatitis, food allergy, and upper respiratory infections. The asthma section provides an in-depth look at sociodemographic factors contributing to asthma morbidity and the barriers to asthma control. New findings on the triggers and therapies of atopic dermatitis and new articles on formula allergy and peanut allergy are presented. Recent publications in the areas of sinusitis and upper respiratory infections are also reviewed.

Adrenergic beta-Agonists↗

X-linked hyper IgM syndrome.

X-linked hyper IgM syndrome is largely caused by defects in the CD40L (CD154). The patients have low levels of IgG and have difficulty with respiratory infections as well as opportunistic infections. The morbidity of this syndrome is high; however, early diagnosis and therapy should reduce morbidity and mortality.

Adolescent↗

Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial.

BACKGROUND: There is a significant group of patients with severe asthma who require chronic use of systemic steroids for control of their disease. These patients are at risk for severe side effects from oral steroids. Intravenous immunoglobulin (IVIG) has immunomodulatory properties, and a few open-label trials have suggested its possible benefit in individuals with severe asthma. OBJECTIVE: This study was designed to assess the potential benefit of IVIG as a steroid-sparing agent in patients with severe asthma. METHODS: Thirty-eight immunocompetent steroid-requiring patients with severe asthma were randomly enrolled in a double-blind, placebo-controlled trial of IVIG. RESULTS: Of the 38 patients enrolled, 28 patients completed the study. A significant reduction in oral steroid requirement was observed in both the IVIG-treated (n = 16) and the placebo-treated (n = 12) patients. Further exploration of the results showed that IVIG, but not placebo, had a significant steroid-sparing effect in patients requiring high doses of oral steroids (ie, >2000 mg in the year before the study). Within this subgroup, IVIG treatment (n = 9) resulted in a significant decrease in oral steroid requirement, with a median of 16.4 mg/day during the pretreatment period to 3 mg/day during the treatment phase (P =. 0078). No significant decrease in oral steroid requirement was observed in placebo-treated patients (n = 8) within this subgroup. Objective and subjective parameters of the patients' asthma were unchanged in spite of the steroid tapering achieved in the group treated with IVIG. CONCLUSION: IVIG may be a useful steroid-sparing agent in patients with severe asthma requiring high doses of oral steroids.

Administration, Oral↗

Malignant spindle cell tumor arising in the mandible of a patient with florid osseous dysplasia.

Florid osseous dysplasia is a non-neoplastic condition of the alveolar processes of the jaws characterized by the replacement of multiple foci of bone by fibrous connective tissue, accompanied by gradual deposition of cementum, bone, or both. The lesions are not associated with inflammatory diseases of the dental pulp or periodontal tissues. In fully developed florid osseous dysplasia, there are multiple lobulated masses in the alveolar bone bilaterally in the mandible and sometimes in the maxilla. This is the first report of a malignancy originating within the jaws of a patient with florid osseous dysplasia. A spindle cell malignancy was diagnosed in the mandible of a 54-year-old black woman whose jaw was affected by florid osseous dysplasia bilaterally. Despite extensive surgery and radiotherapy, the patient died 20 months after diagnosis of the malignancy.

Fatal Outcome↗

Atopic diseases and upper respiratory infections.

This article reviews information on the topics of asthma, allergic rhinitis, atopic dermatitis, food allergy, and upper respiratory infections. The asthma section includes a review of inhaled steroids and their potential side effects. New findings on the pathogenesis, triggers, and therapies of atopic dermatitis and new insights into food hypersensitivity reactions are presented. Recent publications in the areas of allergic rhinoconjunctivitis and upper respiratory infections are also reviewed.

Administration, Inhalation↗

IgE-mediated allergy and desensitization to factor IX in hemophilia B.

BACKGROUND: We describe two patients with factor IX deficiency and high levels of inhibitors to factor IX who developed anaphylaxis to factor IX. OBJECTIVE: The aim of this study was to develop a skin test, RAST, and desensitization protocol for factor IX allergy. METHODS: The patients were evaluated by skin test and RAST to factor IX. They also underwent desensitization to factor IX. RESULTS: Both patients had positive skin test and RAST reactions to factor IX. Control subjects had negative reactions. Both patients were successfully desensitized to factor IX by using two different desensitization protocols. The patients' skin test and RAST reactions to factor IX converted to negative after desensitization. CONCLUSIONS: IgE-mediated reactions to factor IX do occur and may be diagnosed with the use of skin test and RAST. Patients with this type of reaction may be successfully desensitized to factor IX.

Child↗

Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis.

BACKGROUND: Interferon-gamma (IFN-gamma) is a potent cytokine that modulates IL-4-induced immune responses. Atopic dermatitis is associated with increased IgE levels and decreased IFN-gamma production. Recent phase I and phase II studies have suggested that short-term rIFN-gamma therapy is effective in the treatment of severe atopic dermatitis. OBJECTIVE: We evaluated the safety and efficacy of long-term use of rIFN-gamma for severe atopic dermatitis. METHODS: Fifteen patients were treated for a minimum of 22 months with 50 micrograms/m2 rIFN-gamma qd or qod. Patients were monitored every 3 months for safety, efficacy, and linear growth in pediatric patients. RESULTS: Data represented a total of 47 patient years, which included 29 pediatric patient years. There was a statistically significant decrease in mean total body surface area involvement over time (P < .001, ANOVA). Mean total body surface area involvement was 61.6% at baseline and decreased to 18.5% at 24 months (P < .001). Likewise, there was a statistically significant decrease in the clinical severity parameters. The mean total clinical severity score was 11.4 at baseline and decreased to 6.3 at 24 months (P < .001). Statistically significant decreases in WBC, neutrophil counts, and eosinophil counts were observed compared with baseline counts. No other significant laboratory abnormalities or growth problems were seen. CONCLUSIONS: We conclude that rIFN-gamma appears to be a safe long-term therapy for patients with severe atopic dermatitis.

Adolescent↗

Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections.

This review highlights updated information on the topics of atopic dermatitis, food allergy, asthma, allergic rhinitis, and upper respiratory infections. Recent finding on the pathogenesis, triggers, and therapies of atopic dermatitis are discussed. New insights into peanut allergy and formula intolerance are presented. Topics highlighted in the section on asthma include quality of life and quality of care. Recent publications in the areas of allergic rhinoconjunctivitis and upper respiratory infections are also reviewed.

Arachis↗

Periodontal management of gingival overgrowth in the heart transplant patient: a case report.

Heart transplant patients take several medications that could affect their periodontal health. Gingival overgrowth associated with cyclosporin (immunosuppressant agent) and nifedipine (calcium channel blocker) is well documented. Candidal infections often develop because of immune suppression. This report describes the clinical and histopathological changes in the gingival tissues of a heart transplant patient and their management. The gingival tissues exhibited pronounced enlargement. The gingivae were lobulated, and the surface of the lobulations was pebbly and granular. Biopsies showed lobules of fibrous connective tissue covered by stratified squamous epithelium. The outer surfaces were dotted with numerous smaller papillations. Candidal hyphae were present in the superficial layers of the epithelium. The extensive papillary lesions appear to be related to candidiasis and constitute a condition which is best designated as papillary stomatitis. Hyperplastic gingival tissues were excised, and the patient was placed on periodic maintenance. One-year postoperative follow-up showed minor gingival growth.

Calcium Channel Blockers↗

Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections.

This review highlights recent information on the topics of atopic diseases and upper respiratory infections. Recent findings on the costs and therapies of atopic dermatitis are discussed. New insights into egg allergy, peanut allergy, food-induced exercise anaphylaxis, and the management of food allergy are presented. Topics highlighted in the section on asthma include airway remodeling and anti-inflammatory therapy, leukotriene synthesis inhibitors and receptor antagonists, steroid resistance and alternative therapy, and new delivery systems. Recent publications in the areas of allergic rhinoconjunctivitis and upper respiratory infections are also reviewed.

Anti-Asthmatic Agents↗

Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study.

OBJECTIVE: To determine the risk of and risk factors for hepatitis C virus (HCV) infection among persons with immune deficiencies who had received intravenous immune globulin (IGIV) between March 1993 and February 1994. DESIGN: Retrospective cohort study. SETTING: An immunology program in a tertiary care hospital. PATIENTS: Of 341 persons who had received IGIV between March 1, 1993, and February 22, 1994, 278 (82%) were enrolled. The mean age for the enrolled persons was 9 years, and 99% had primary immune deficiencies. MAIN OUTCOME MEASURES: Evidence of HCV infection by detection in sera of antibody to HCV and/or HCV RNA by reverse transcriptase polymerase chain reaction. RESULTS: Twenty-three (11%) of 210 persons who received the IGIV Gammagard (Baxter Healthcare Corporation, Deerfield, Ill) became infected compared with none of 52 persons who received exclusively other IGIV products (P=.01). In a multivariate analysis, HCV infection was associated only with Gammagard produced from plasma screened by second-generation (multiantigen) anti-HCV tests (P=.03). Hepatitis C virus RNA was detected in Gammagard, and the risk of transmission to recipients increased with increasing quantity of HCV RNA infused, from 0 for those who received no HCV RNA-positive lots to 29% for the quartile of patients receiving the greatest amount (P<.001). At least 9 different lots of Gammagard were required to account for all cases. CONCLUSION: Gammagard was the only IGIV product implicated in the transmission of HCV. Infection was associated with higher quantities of HCV RNA in Gammagard produced from second-generation anti-HCV-screened plasma. Further studies are needed to determine reasons for the infectivity of Gammagard, and viral inactivation and removal steps are needed to ensure the safety of IGIV products.

Alanine Transaminase↗